research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
research Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.
research Janus kinase (JAK)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research 0350 Impact of switching janus kinase inhibitors in the treatment of severe alopecia areata
Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.
research Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children
JAK inhibitors may help treat alopecia areata in children, but their safety needs careful evaluation.
research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
research Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
research Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Ruxolitinib found to cause eyelash growth: a case report
Ruxolitinib treatment may cause eyelash growth.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Pathomechanisms of immune-mediated alopecia
The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
research The Diagnosis and Treatment of Hair and Scalp Diseases
Hair loss requires customized treatments based on its various causes and types.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Novedades terapéuticas en tricología
Recent advances in hair loss treatments show significant progress.
research Treatments options for alopecia
The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.